{
  "feed_url": "https://gbilder.com/tags/tech-transfer/feed.json",
  "home_page_url": "https://gbilder.com/tags/tech-transfer/",
  "items": [
    {
      "content_html": "\n  \u003cp class=\"bafflegab-bookmark\"\u003eBookmarked \u003ca class=\"u-bookmark-of\" href=\"https://www.medrxiv.org/content/10.1101/2021.04.08.21255103v1\"\u003ehttps://www.medrxiv.org/content/10.1101/2021.04.08.21255103v1\u003c/a\u003e\u003c/p\u003e\n  \u003cdiv class=\"e-content\"\u003e\u003cp\u003eOur study identified that public funding accounted for 97.1-99.0% of the funding towards the R\u0026amp;D of ChAdOx and the Oxford-AstraZeneca vaccine. We furthermore encountered a severe lack of transparency in research funding reporting mechanisms.\u003c/p\u003e\u003c/div\u003e\n",
      "date_published": "2021-06-06T23:17:58+02:00",
      "external_url": "https://www.medrxiv.org/content/10.1101/2021.04.08.21255103v1",
      "id": "https://gbilder.com/bookmarks/01M4EHRV5044FJVNPAKGKK0RMA/",
      "tags": [
        "patents",
        "tech-transfer"
      ],
      "title": "Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology | medRxiv",
      "url": "https://gbilder.com/bookmarks/01M4EHRV5044FJVNPAKGKK0RMA/"
    }
  ],
  "language": "en",
  "title": "#tech-transfer · Louche Cannon",
  "version": "https://jsonfeed.org/version/1.1"
}